Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Ever since joining Sevilla on loan in January 2023, centerback Loic Bade has stood as a crucial component to the Spanish club ...

BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...

After securing Ernest Poku’s transfer, Bayer Leverkusen are continuously looking to strengthen their squad for the 2025/26 ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core ...

An announcement from Board of Education President Steven Blair on Friday said Mike Dominguez resigned July 31 to "pursue ...